

Stewart Thomas Cole

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7851249/publications.pdf>

Version: 2024-02-01

96
papers

11,040
citations

41344
49
h-index

40979
93
g-index

104
all docs

104
docs citations

104
times ranked

9524
citing authors

#	ARTICLE	IF	CITATIONS
1	Mycobacterium tuberculosis EspK Has Active but Distinct Roles in the Secretion of EsxA and EspB. Journal of Bacteriology, 2022, 204, e0006022.	2.2	10
2	Mycobacterium leprae diversity and population dynamics in medieval Europe from novel ancient genomes. BMC Biology, 2021, 19, 220.	3.8	14
3	A new paradigm for leprosy diagnosis based on host gene expression. PLoS Pathogens, 2021, 17, e1009972.	4.7	11
4	Leprosy in wild chimpanzees. Nature, 2021, 598, 652-656.	27.8	30
5	Structural and DNA binding properties of mycobacterial integration host factor mIHF. Journal of Structural Biology, 2020, 209, 107434.	2.8	3
6	High resolution CryoEM structure of the ring-shaped virulence factor EspB from Mycobacterium tuberculosis. Journal of Structural Biology: X, 2020, 4, 100029.	1.3	17
7	FasR Regulates Fatty Acid Biosynthesis and Is Essential for Virulence of Mycobacterium tuberculosis. Frontiers in Microbiology, 2020, 11, 586285.	3.5	1
8	6,11-Dioxobenzo[<i>f</i>]pyrido[1,2- <i>a</i>]indoles Kill <i>Mycobacterium tuberculosis</i> by Targeting Iron-Sulfur Protein Rv0338c (IspQ), A Putative Redox Sensor. ACS Infectious Diseases, 2020, 6, 3015-3025.	3.8	9
9	Comparison of target enrichment strategies for ancient pathogen DNA. BioTechniques, 2020, 69, 455-459.	1.8	17
10	Advanced Quantification Methods To Improve the 18b Dormancy Model for Assessing the Activity of Tuberculosis Drugs <i>In Vitro</i> . Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	3
11	Emergence of Mycobacterium leprae Rifampin Resistance Evaluated by Whole-Genome Sequencing after 48 Years of Irregular Treatment. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	7
12	Population Genomics of Mycobacterium leprae Reveals a New Genotype in Madagascar and the Comoros. Frontiers in Microbiology, 2020, 11, 711.	3.5	15
13	Genomic Characterization of Mycobacterium leprae to Explore Transmission Patterns Identifies New Subtype in Bangladesh. Frontiers in Microbiology, 2020, 11, 1220.	3.5	20
14	Polarly Localized EccE ₁ Is Required for ESX-1 Function and Stabilization of ESX-1 Membrane Proteins in Mycobacterium tuberculosis. Journal of Bacteriology, 2020, 202, .	2.2	7
15	New 2-Ethylthio-4-methylaminoquinazoline derivatives inhibiting two subunits of cytochrome bc1 in Mycobacterium tuberculosis. PLoS Pathogens, 2020, 16, e1008270.	4.7	38
16	Celebrating 130 years of achievement by the Institut Pasteur. Microbes and Infection, 2019, 21, 189.	1.9	0
17	Synthesis, biology, computational studies and <i>in vitro</i> controlled release of new isoniazid-based adamantane derivatives. Future Medicinal Chemistry, 2019, 11, 2779-2802.	2.3	4
18	Design, Synthesis and <i>in vitro</i> Controlled Release of New Adamantanodiarlylketone Antimycobacterials. ChemistrySelect, 2019, 4, 11048-11051.	1.5	0

#	ARTICLE	IF	CITATIONS
19	Monitoring Tuberculosis Drug Activity in Live Animals by Using Near-Infrared Fluorescence Imaging. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	2
20	Celebrating 130 years of achievement by the Institut Pasteur. Genes and Immunity, 2019, 20, 341-341.	4.1	0
21	Synthesis of diphenoxyadamantane alkylamines with pharmacological interest. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1278-1281.	2.2	9
22	Phylogenomics and antimicrobial resistance of the leprosy bacillus Mycobacterium leprae. Nature Communications, 2018, 9, 352.	12.8	95
23	Promoter mutagenesis for fine-tuning expression of essential genes in <i>Mycobacterium tuberculosis</i> . Microbial Biotechnology, 2018, 11, 238-247.	4.2	13
24	EspL is essential for virulence and stabilizes EspE, EspF and EspH levels in Mycobacterium tuberculosis. PLoS Pathogens, 2018, 14, e1007491.	4.7	33
25	Essential Nucleoid Associated Protein mHf (Rv1388) Controls Virulence and Housekeeping Genes in Mycobacterium tuberculosis. Scientific Reports, 2018, 8, 14214.	3.3	19
26	Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis. MBio, 2018, 9, .	4.1	52
27	Evidence of zoonotic leprosy in Pará, Brazilian Amazon, and risks associated with human contact or consumption of armadillos. PLoS Neglected Tropical Diseases, 2018, 12, e0006532.	3.0	65
28	Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	49
29	Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169). Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	48
30	Ancient genomes reveal a high diversity of Mycobacterium leprae in medieval Europe. PLoS Pathogens, 2018, 14, e1006997.	4.7	98
31	Rv3852 (H-NS) of Mycobacterium tuberculosis Is Not Involved in Nucleoid Compaction and Virulence Regulation. Journal of Bacteriology, 2017, 199, .	2.2	9
32	Insights from the Genome Sequence of <i>Mycobacterium lepraemurium</i> : Massive Gene Decay and Reductive Evolution. MBio, 2017, 8, .	4.1	16
33	<i>ESX-1</i> forms a filamentous structure in the cell envelope of <i>Mycobacterium tuberculosis</i> and impacts <i>ESX-1</i> secretion. Molecular Microbiology, 2017, 103, 26-38.	2.5	77
34	The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis. ACS Infectious Diseases, 2017, 3, 5-17.	3.8	83
35	Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors. Drug Discovery Today, 2017, 22, 526-533.	6.4	55
36	Tuberculosis drug discovery needs public-private consortia. Drug Discovery Today, 2017, 22, 477-478.	6.4	12

#	ARTICLE	IF	CITATIONS
37	Whole genome sequencing distinguishes between relapse and reinfection in recurrent leprosy cases. PLoS Neglected Tropical Diseases, 2017, 11, e0005598.	3.0	35
38	Transcription facilitated genome-wide recruitment of topoisomerase I and DNA gyrase. PLoS Genetics, 2017, 13, e1006754.	3.5	56
39	Inhibiting <i>Mycobacterium tuberculosis</i> within and without. Philosophical Transactions of the Royal Society B: Biological Sciences, 2016, 371, 20150506.	4.0	52
40	Transmission of Drug-Resistant Leprosy in Guinea-Conakry Detected Using Molecular Epidemiological Approaches: Table 1.. Clinical Infectious Diseases, 2016, 63, 1482-1484.	5.8	25
41	Characterization of DprE1-Mediated Benzothiazinone Resistance in <i>Mycobacterium tuberculosis</i> . Antimicrobial Agents and Chemotherapy, 2016, 60, 6451-6459.	3.2	36
42	Red squirrels in the British Isles are infected with leprosy bacilli. Science, 2016, 354, 744-747.	12.6	138
43	Genomic and transcriptomic analysis of the streptomycin-dependent <i>Mycobacterium tuberculosis</i> strain 18b. BMC Genomics, 2016, 17, 190.	2.8	18
44	Zoonotic Leprosy in the Southeastern United States. Emerging Infectious Diseases, 2015, 21, 2127-34.	4.3	100
45	The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from <i>Mycobacterium tuberculosis</i> . Antimicrobial Agents and Chemotherapy, 2015, 59, 4446-4452.	3.2	85
46	Structure of EspB, a secreted substrate of the ESX-1 secretion system of <i>Mycobacterium tuberculosis</i> . Journal of Structural Biology, 2015, 191, 236-244.	2.8	51
47	<i>Mycobacterium tuberculosis</i> Differentially Activates cGAS- and Inflammasome-Dependent Intracellular Immune Responses through ESX-1. Cell Host and Microbe, 2015, 17, 799-810.	11.0	341
48	Lansoprazole is an antituberculous prodrug targeting cytochrome bc1. Nature Communications, 2015, 6, 7659.	12.8	141
49	Thiophenecarboxamide Derivatives Activated by EthA Kill <i>Mycobacterium tuberculosis</i> by Inhibiting the CTP Synthetase PyrG. Chemistry and Biology, 2015, 22, 917-927.	6.0	72
50	DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization. ACS Chemical Biology, 2015, 10, 1631-1636.	3.4	123
51	Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against <i>Mycobacterium tuberculosis</i> . Antimicrobial Agents and Chemotherapy, 2015, 59, 4457-4463.	3.2	105
52	Insight into the evolution and origin of leprosy bacilli from the genome sequence of <i>Mycobacterium lepromatosis</i> . Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 4459-4464.	7.1	134
53	CtrA Protein Rv3789 Is Required for Arabinosylation of Arabinogalactan in <i>Mycobacterium tuberculosis</i> . Journal of Bacteriology, 2015, 197, 3686-3697.	2.2	26
54	Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with <i>Mycobacterium tuberculosis</i> decaprenylphosphoryl- β -D-ribose 2-oxidase. Bioorganic and Medicinal Chemistry, 2015, 23, 7694-7710.	3.0	44

#	ARTICLE	IF	CITATIONS
55	2-Carboxyquinoxalines Kill <i>Mycobacterium tuberculosis</i> through Noncovalent Inhibition of DprE1. <i>ACS Chemical Biology</i> , 2015, 10, 705-714.	3.4	116
56	The PhoP-Dependent ncRNA Mcr7 Modulates the TAT Secretion System in <i>Mycobacterium tuberculosis</i> . <i>PLoS Pathogens</i> , 2014, 10, e1004183.	4.7	127
57	In Vitro and In Vivo Activities of Three Oxazolidinones against Nonreplicating <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3217-3223.	3.2	53
58	New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 327-340.	9.1	302
59	Towards a new combination therapy for tuberculosis with next generation benzothiazinones. <i>EMBO Molecular Medicine</i> , 2014, 6, 372-383.	6.9	311
60	<i>EspL</i> regulates the <i>ESX-1</i> secretion system in response to <i>ATP</i> levels in <i>Mycobacterium tuberculosis</i> . <i>Molecular Microbiology</i> , 2014, 93, 1057-1065.	2.5	27
61	Assessing the essentiality of the decaprenylphosphoate arabinofuranose pathway in <i>Mycobacterium tuberculosis</i> using conditional mutants. <i>Molecular Microbiology</i> , 2014, 92, 194-211.	2.5	76
62	Anticytolytic Screen Identifies Inhibitors of Mycobacterial Virulence Protein Secretion. <i>Cell Host and Microbe</i> , 2014, 16, 538-548.	11.0	83
63	<i>Mycobacterium leprae</i> genomes from a British medieval leprosy hospital: towards understanding an ancient epidemic. <i>BMC Genomics</i> , 2014, 15, 270.	2.8	60
64	Cross-Resistance between Clofazimine and Bedaquiline through Upregulation of <i>MmpL5</i> in <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2979-2981.	3.2	376
65	<i>Mycobacterium tuberculosis</i> <i>EspB</i> binds phospholipids and mediates <i>EsaA</i> -independent virulence. <i>Molecular Microbiology</i> , 2013, 89, 1154-1166.	2.5	65
66	Database resources for the tuberculosis community. <i>Tuberculosis</i> , 2013, 93, 12-17.	1.9	27
67	Advances in the development of new tuberculosis drugs and treatment regimens. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 388-404.	46.4	726
68	Genome-Wide Comparison of Medieval and Modern <i>Mycobacterium leprae</i> . <i>Science</i> , 2013, 341, 179-183.	12.6	313
69	High-resolution transcriptome and genome-wide dynamics of RNA polymerase and NusA in <i>Mycobacterium tuberculosis</i> . <i>Nucleic Acids Research</i> , 2013, 41, 961-977.	14.5	41
70	Phenotypic Profiling of <i>Mycobacterium tuberculosis</i> <i>EspA</i> Point Mutants Reveals that Blockage of ESAT-6 and CFP-10 Secretion <i>In Vitro</i> Does Not Always Correlate with Attenuation of Virulence. <i>Journal of Bacteriology</i> , 2013, 195, 5421-5430.	2.2	47
71	Streptomycin-Starved <i>Mycobacterium tuberculosis</i> 18b, a Drug Discovery Tool for Latent Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5782-5789.	3.2	88
72	<i>EspD</i> Is Critical for the Virulence-Mediating <i>ESX-1</i> Secretion System in <i>Mycobacterium tuberculosis</i> . <i>Journal of Bacteriology</i> , 2012, 194, 884-893.	2.2	66

#	ARTICLE	IF	CITATIONS
73	Structural Basis for Benzothiazinone-Mediated Killing of <i>Mycobacterium tuberculosis</i> . Science Translational Medicine, 2012, 4, 150ra121.	12.4	159
74	Benzothiazinones Are Suicide Inhibitors of Mycobacterial Decaprenylphosphoryl- β -D-ribofuranose 2-Oxidase DprE1. Journal of the American Chemical Society, 2012, 134, 912-915.	13.7	155
75	Virulence Regulator EspR of <i>Mycobacterium tuberculosis</i> Is a Nucleoid-Associated Protein. PLoS Pathogens, 2012, 8, e1002621.	4.7	115
76	Probable Zoonotic Leprosy in the Southern United States. New England Journal of Medicine, 2011, 364, 1626-1633.	27.0	296
77	The MycoBrowser portal: A comprehensive and manually annotated resource for mycobacterial genomes. Tuberculosis, 2011, 91, 8-13.	1.9	355
78	TubercuList – 10 years after. Tuberculosis, 2011, 91, 1-7.	1.9	387
79	ESAT-6 Secretion-Independent Impact of ESX-1 Genes espF and espG1 on Virulence of <i>Mycobacterium tuberculosis</i> . Journal of Infectious Diseases, 2011, 203, 1155-1164.	4.0	66
80	<i>Mycobacterium leprae</i> : genes, pseudogenes and genetic diversity. Future Microbiology, 2011, 6, 57-71.	2.0	106
81	Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis, 2010, 90, 354-360.	1.9	92
82	Development of a repressible mycobacterial promoter system based on two transcriptional repressors. Nucleic Acids Research, 2010, 38, e134-e134.	14.5	74
83	Systematic Genetic Nomenclature for Type VII Secretion Systems. PLoS Pathogens, 2009, 5, e1000507.	4.7	233
84	High Content Screening Identifies Decaprenyl-Phosphoribose 2-Epimerase as a Target for Intracellular Antimycobacterial Inhibitors. PLoS Pathogens, 2009, 5, e1000645.	4.7	281
85	Genome-wide regulon and crystal structure of Blal (Rv1846c) from <i>Mycobacterium tuberculosis</i> . Molecular Microbiology, 2009, 71, 1102-1116.	2.5	61
86	Comparative genomic and phylogeographic analysis of <i>Mycobacterium leprae</i> . Nature Genetics, 2009, 41, 1282-1289.	21.4	360
87	From functional genomics to systems (micro)biology. Current Opinion in Microbiology, 2009, 12, 528-530.	5.1	1
88	Benzothiazinones Kill <i>Mycobacterium tuberculosis</i> by Blocking Arabinan Synthesis. Science, 2009, 324, 801-804.	12.6	660
89	Comprehensive proteome analysis of <i>Mycobacterium ulcerans</i> and quantitative comparison of mycolactone biosynthesis. Proteomics, 2008, 8, 3124-3138.	2.2	26
90	Insights from the complete genome sequence of <i>Mycobacterium marinum</i> on the evolution of <i>Mycobacterium tuberculosis</i> . Genome Research, 2008, 18, 729-741.	5.5	471

#	ARTICLE	IF	CITATIONS
91	Dissection of ESAT-6 System 1 of Mycobacterium tuberculosis and Impact on Immunogenicity and Virulence. Infection and Immunity, 2006, 74, 88-98.	2.2	279
92	Functional Analysis of Early Secreted Antigenic Target-6, the Dominant T-cell Antigen of Mycobacterium tuberculosis, Reveals Key Residues Involved in Secretion, Complex Formation, Virulence, and Immunogenicity. Journal of Biological Chemistry, 2005, 280, 33953-33959.	3.4	133
93	On the Origin of Leprosy. Science, 2005, 308, 1040-1042.	12.6	441
94	Comparative Analysis of B- and T-Cell Epitopes of Mycobacterium leprae and Mycobacterium tuberculosis Culture Filtrate Protein 10. Infection and Immunity, 2004, 72, 3161-3170.	2.2	41
95	Bacterial Artificial Chromosome-Based Comparative Genomic Analysis Identifies Mycobacterium microti as a Natural ESAT-6 Deletion Mutant. Infection and Immunity, 2002, 70, 5568-5578.	2.2	152
96	Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines <i>Mycobacterium bovis</i> BCG and <i>Mycobacterium microti</i>. Molecular Microbiology, 2002, 46, 709-717.	2.5	645